September 19 2017 - Is Allergan CEO Brent Saunders breaking his 'social contract' on drug pricing
Flag link:
This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge
This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge
Stat
Pharma CEOs
Allergan
Brent Saunders
drug pricing
Restasis
Flag link:
Signaling a major shift at the FDA, regulators put Amicus’ once-spurned drug on fast track
Signaling a major shift at the FDA, regulators put Amicus’ once-spurned drug on fast track
Endpoints
FDA
Amicus Therapeutics
migalastat
Fabry disease
fast track
Flag link:
5 Trends shaping the pharma sales force
5 Trends shaping the pharma sales force
BioPharma Dive
pharma sales
drug reps
specialty pharma
physician access
samples
Flag link:
Digital pharma sales technologies soar
Digital pharma sales technologies soar
BioPharma Dive
physicians
drug reps
pharma sales
digital marketing
Flag link:
Ex-Glaxo CEO Witty joins Hatteras as venture partner
Ex-Glaxo CEO Witty joins Hatteras as venture partner
Fierce Biotech
Pharma CEOs
GSK
Andrew Witty
Hatteras Venture Partners
Flag link:
J&J, BARDA join forces to prep for pandemic flu, inking deal for vaccine and drug R&D
J&J, BARDA join forces to prep for pandemic flu, inking deal for vaccine and drug R&D
Fierce Pharma
JNJ
BARDA
pandemic flu
vaccines
R&D
Flag link:
With CRO consolidation in full swing, Catalent inks a $950M deal to acquire Cook Pharmica
With CRO consolidation in full swing, Catalent inks a $950M deal to acquire Cook Pharmica
Endpoints
CROs
Catalent
M&A
Cook Pharmica
R&D
Flag link:
Will an Open-Access Clinical Trials Database Improve Drug Development?
Will an Open-Access Clinical Trials Database Improve Drug Development?
Xtalks
clinical trials
clinical trial data
drug development
OZMOSI
Flag link:
Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors
Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors
Motley Fool
Gilead Sciences
Kite Pharma
M&A
investors
Flag link:
Nabriva shares leap higher on antibiotic trial success
Nabriva shares leap higher on antibiotic trial success
BioPharma Dive
Nabriva Therapeutics
antibiotics
clinical trials
lefamulin
Flag link:
On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy
On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy
Xconomy
CAR-T
Novartis
Seattle Children's
pediatric cancer
ALL
gene therapy
Flag link:
FDA clears Medtronic's next-generation spinal cord stimulator
FDA clears Medtronic's next-generation spinal cord stimulator
Fierce Biotech
FDA
devices
Medtronic
spinal cord stimulator
Intellis
Flag link:
GSK Loses Bid For New Trial in Attorney Suicide Case
GSK Loses Bid For New Trial in Attorney Suicide Case
Bloomberg Law
GSK
Paxil
suicide
antidepressants
Flag link:
Infographic: Pharma sales force by the numbers
Infographic: Pharma sales force by the numbers
BioPharma Dive
drug reps
Flag link:
Smaller sales forces get the job done in rare disease
Smaller sales forces get the job done in rare disease
BioPharma Dive
drug reps
sales force
rare disease
Taro Pharmaceuticals
Flag link:
September 18 2017 - Sanofi and Amgen tout benefits for PCSK9 inhibitors for diabetic patients
Flag link:
Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients
Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients
Fierce Pharma
Sanofi
Amgen
PCSK9 inhibitors
diabetes
Regeneron
Praluent
Repatha
Flag link:
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
Motley Fool
cancer
cancer immunotherapies
Opdivo
Bristol-Myers Squibb
Keytruda
Merck
Yervoy
Flag link:
5 Ways to Predict Patent Litigation Outcomes
5 Ways to Predict Patent Litigation Outcomes
Drug Patent Watch
patents
patent lawsuits
Flag link: